NCT01728467

The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes

Phase 2 Randomised, Double-blind, Placebo-controlled, Cross-over Study for the Assessment of Glucose Metabolism Changes With RVX000222 in Individuals With Pre-diabetes

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Resverlogix Corp · Industry
• Sex: Male
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study builds on data that high-density lipoprotein (HDL) has a number of potentially beneficial effects including directly modulating glucose metabolism through multiple mechanisms. The primary objective of this study is to determine the effects of RVX000222 on postprandial plasma glucose in male individuals with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), during a frequently sampled oral glucose tolerance test (OGTT).

Conditions

• Diabetes

Interventions

Type	Name	Description
DRUG	RVX000222	capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
DRUG	Placebo, RVX000222	capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days

Timeline

• Start date: 2012-11-01
• Primary completion: 2014-03-01
• Completion: 2014-03-01
• First posted: 2012-11-19
• Last updated: 2014-04-02

Locations

1 site across 1 country: Australia